Louise Roulin

853 total citations
18 papers, 90 citations indexed

About

Louise Roulin is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Louise Roulin has authored 18 papers receiving a total of 90 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Louise Roulin's work include CAR-T cell therapy research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Louise Roulin is often cited by papers focused on CAR-T cell therapy research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Louise Roulin collaborates with scholars based in France and United States. Louise Roulin's co-authors include Corinne Haïoun, François Lemonnier, Fabien Le Bras, Jehan Dupuis, Karim Belhadj, Elsa Poullot, Taoufik El Gnaoui, Thibaud Damy, Emmanuel Itti and Philippe Gaulard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Louise Roulin

13 papers receiving 90 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Louise Roulin France	6	47	36	32	28	14	18	90
Lisa von Wenserski Germany	5	42 0.9×	25 0.7×	33 1.0×	22 0.8×	8 0.6×	5	104
Danielle Leão Cordeiro de Farias Brazil	6	35 0.7×	33 0.9×	19 0.6×	40 1.4×	17 1.2×	15	93
Shamzah Araf United Kingdom	5	45 1.0×	64 1.8×	23 0.7×	22 0.8×	4 0.3×	11	114
Jaime Verdú‐Amorós Spain	6	62 1.3×	74 2.1×	14 0.4×	39 1.4×	30 2.1×	10	131
Camila Peña Chile	6	36 0.8×	28 0.8×	43 1.3×	26 0.9×	54 3.9×	43	111
Shlomzion Aumann Israel	7	51 1.1×	24 0.7×	97 3.0×	33 1.2×	53 3.8×	25	160
Bella Biderman Russia	5	23 0.5×	48 1.3×	32 1.0×	56 2.0×	26 1.9×	46	115
Pilar Martínez‐Sánchez Spain	7	58 1.2×	31 0.9×	50 1.6×	24 0.9×	69 4.9×	18	129
Betty Prine United States	5	33 0.7×	40 1.1×	34 1.1×	51 1.8×	40 2.9×	6	112
Emily C. Ayers United States	5	35 0.7×	33 0.9×	11 0.3×	17 0.6×	12 0.9×	19	69

Countries citing papers authored by Louise Roulin

Since Specialization

Citations

This map shows the geographic impact of Louise Roulin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Roulin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Roulin more than expected).

Fields of papers citing papers by Louise Roulin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Roulin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Roulin. The network helps show where Louise Roulin may publish in the future.

Co-authorship network of co-authors of Louise Roulin

This figure shows the co-authorship network connecting the top 25 collaborators of Louise Roulin. A scholar is included among the top collaborators of Louise Roulin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise Roulin. Louise Roulin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Bachy, Emmanuel, François‐Xavier Gros, Roberta Di Blasi, et al.. (2025). Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study. Blood Advances. 9(10). 2500–2510.

Ferrant, Emmanuelle, Rémy Duléry, David Beauvais, et al.. (2025). Anti‐CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR‐T registry. British Journal of Haematology. 207(3). 1143–1147.

Blasi, Roberta Di, Louise Roulin, Véronique Meignin, et al.. (2025). TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas. Blood Advances. 9(18). 4693–4704.

Aymard, M., Morgane Cheminant, Roch Houot, et al.. (2025). Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group. Blood Advances. 10(1). 75–82.

Loganadane, Gokoulakrichenane, et al.. (2024). Combined daratumumab-pomalidomide and ultra-fractionated whole breast irradiation is safe!. Reports of Practical Oncology & Radiotherapy. 29(3). 408–410. 1 indexed citations

Aymard, M., Morgane Cheminant, Roch Houot, et al.. (2024). Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group. Blood. 144(Supplement 1). 239–239.

Blanc‐Durand, Paul, Louise Roulin, Charlotte Lafont, et al.. (2023). Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort. British Journal of Haematology. 202(1). 54–64. 12 indexed citations

Beldi‐Ferchiou, Asma, Vincent Audard, François Lemonnier, et al.. (2022). Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis. SHILAP Revista de lepidopterología. 3(3). 828–837. 3 indexed citations

Fourati, Slim, Anne Le Bouter, Fabien Le Bras, et al.. (2022). Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies. Clinical Microbiology and Infection. 28(6). 885.e7–885.e11. 10 indexed citations

10.

Bachy, Emmanuel, David Beauvais, Rémy Duléry, et al.. (2022). Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry. Blood. 140(Supplement 1). 3803–3804. 5 indexed citations

11.

Bachy, Emmanuel, Guillaume Cartron, Franck Morschhauser, et al.. (2022). Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry. Blood. 140(Supplement 1). 1325–1327. 1 indexed citations

12.

Belhadj, Karim, Jehan Dupuis, Louise Roulin, et al.. (2021). Venetoclax induces profound and sustained responses in patients with relapsed/refractory light‐chain amyloidosis. British Journal of Haematology. 193(3). 674–677. 13 indexed citations

13.

Belhadj, Karim, Vincent Camus, Elsa Poullot, et al.. (2021). Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leukemia & lymphoma. 62(9). 2161–2168. 24 indexed citations

14.

Bras, Fabien Le, Jehan Dupuis, Silvia Oghina, et al.. (2020). Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment. Leukemia & lymphoma. 62(4). 979–983. 7 indexed citations

15.

Bras, Fabien Le, Jehan Dupuis, François Lemonnier, et al.. (2019). Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.. Journal of Clinical Oncology. 37(15_suppl). e19538–e19538. 7 indexed citations

16.

Belhadj, Karim, Vincent Camus, Liana Veresezan, et al.. (2019). Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation. Blood. 134(Supplement_1). 4115–4115. 1 indexed citations

17.

Roulin, Louise, Aline Massé, Dominique Bluteau, et al.. (2015). Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells. Blood. 126(23). 2588–2588. 2 indexed citations

18.

Ghrenassia, E., Louise Roulin, Christophe Marzac, et al.. (2014). The Spectrum of Chronic CD8+ T-Cell Expansions: Clinical Features in 14 Patients. PLoS ONE. 9(3). e91505–e91505. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact